TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update
TG Therapeutics (NASDAQ: TGTX) will host a conference call on Thursday, February 26, 2026 at 8:30 AM ET to discuss fourth-quarter and full-year 2025 results and provide a 2026 business outlook.
Rhea-AI Summary
TG Therapeutics (NASDAQ: TGTX) will host a conference call on Thursday, February 26, 2026 at 8:30 AM ET to discuss fourth-quarter and full-year 2025 results and provide a 2026 business outlook.
Michael S. Weiss, Chairman and CEO, will host. A live webcast and a 30-day replay will be available on the company's Investors & Media Events page. Financial results will be issued in a press release prior to the call.
Positive
- None.
Negative
- None.
Details
News Market Reaction – TGTX
In the Feb 23 session, TGTX gained 3.52%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Conference date
- February 26, 2026
- Scheduled earnings and business update call
- Conference time
- 8:30 AM ET
- Start time for Q4 and FY 2025 call
- Replay period
- 30 days
- Duration audio recording remains available on website
- U.S. dial-in number
- 1-877-407-8029
- Phone access for conference call participation
Previous Conferences,earnings Reports
-
Announced timing and access details for Q3 2025 earnings call.
-
Set date and logistics for Q2 2025 earnings and business update.
-
Announced first quarter 2025 earnings call and webcast details.
-
Scheduled Q4 and full-year 2024 results call and 2025 outlook.
-
Outlined date for Q3 2024 earnings call and business update.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
earnings call financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call to be Held Thursday, February 26, 2026, at 8:30 am ET
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Thursday, February 26, 2026, at 8:30 AM ET to discuss results for the fourth quarter and full year 2025 and to provide a business outlook for 2026. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
| CONTACT: | |
| Investor Relations | |
| Email: ir@tgtxinc.com | |
| Telephone: 1.877.575.TGTX (8489), Option 4 | |
| Media Relations: | |
| Email: media@tgtxinc.com | |
| Telephone: 1.877.575.TGTX (8489), Option 6 | |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.